Cart
sales@molnova.com
BLU-945
CAS No. 2660250-10-0
BLU-945( —— )
Catalog No. M37656 CAS No. 2660250-10-0
BLU-945 is a reversible, potent, highly selective, and orally available epidermal growth factor receptor tyrosine kinase inhibitor (TKIs).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 147 | Get Quote |
|
| 5MG | 203 | Get Quote |
|
| 10MG | 304 | Get Quote |
|
| 25MG | 502 | Get Quote |
|
| 50MG | 753 | Get Quote |
|
| 100MG | 1132 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameBLU-945
-
NoteResearch use only, not for human use.
-
Brief DescriptionBLU-945 is a reversible, potent, highly selective, and orally available epidermal growth factor receptor tyrosine kinase inhibitor (TKIs).
-
DescriptionBLU-945 is a potent, highly selective, reversible and orally active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKIs). BLU-945 can effectively inhibit EGFR with L858R and/or exon 19 deletion mutation, T790M mutation and C797S mutation. BLU-945 can be used for the research of lung cancer including non-small cell lung cancer (NSCLC).
-
In Vitro——
-
In VivoAnimal Model:triple-mutant osimertinib-resistant Ba/F3 CDX and PDCX models Dosage:0-100 mg/kg Administration:oral, twice daily Result:Showed significant tumor regression in an osimertinib-resistant EGFR ex19del/T790M/C797S PDCX.
-
Synonyms——
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2660250-10-0
-
Formula Weight556.7
-
Molecular FormulaC28H37FN6O3S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (179.63 mM; Ultrasonic )
-
SMILESCO[C@@H]1CCN(C[C@@H]1F)c1nccc(Nc2cc3c(ccc(N4C[C@H](CS(C)(=O)=O)[C@H]4C)c3cn2)C(C)C)n1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. John Emmerson Campbell, et al. Inhibitors of mutant forms of egfr. Patent WO2021133809A1.
molnova catalog
related products
-
AST-1306
AST-1306 is a novel irreversible inhibitor of EGFR and ErbB2 with IC50 of 0.5 nM and 3 nM, also effective in mutation EGFR T790M/L858R.
-
EGFR-IN-8
EGFR-IN-8 can be a promising candidate for further development to target EGFR TKI-resistant NSCLC. EGFR-IN-8 is a dual EGFR and c-Met inhibitor.
-
Sapitinib
Sapitinib (AZD-8931, AZD8931) is a equipotent, reversible inhibitor of EGFR, ErbB2 and ErbB3 with IC50 of 4. 3 and 4 nM (phosphorylation inhibition), respectively.
